Novo Nordisk's new obesity drug data disappoints again, shares fall
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...
Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...
The company also offers Rybelsus ... shortages limited to the lowest dose for Wegovy. Resolving these supply issues will be crucial for Novo Nordisk to capitalize on the growing demand for ...
Novo Nordisk said on Wednesday it would begin selling ... highest-strength doses of the drug through LillyDirect. The lowest dose costs $349 a month and the others cost $499 a month.
Novo Nordisk said Wednesday it will sell Wegovy ... Last week, Eli Lilly lowered the price of its starting dose to $349 a month and added two higher doses for $499 a month, though it hasn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback